Fresenius Medical Care North America Inc. to pay $5.2 million to resolve increased testing to bill Medicare for unnecessary tests

Fresenius Medical Care Holdings, Inc., doing business as Fresenius Medical Care North America, Inc., the largest operator of kidney dialysis clinics in the United States, will pay $5.2 million to resolve allegations that the company tested dialysis patients for Hepatitis B surface antigen more frequently than was medically necessary, so they could bill Medicare for unnecessary tests (See related link).

 

Christopher Drennen, a former employee with Fresenius, brought forth the allegations through a whistleblower lawsuit. With this settlement, he will receive 27.5% of the recovery.